Last reviewed · How we verify
raloxifen
At a glance
| Generic name | raloxifen |
|---|---|
| Sponsor | Organon and Co |
| Target | Aldehyde oxidase, HLA class I histocompatibility antigen, A-3 alpha chain, 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Postmenopausal osteoporosis
- Prevention of Breast Carcinoma
Common side effects
- Hot flashes
- Leg cramps
- Peripheral edema
- Flu syndrome
- Arthralgia
- Sweating
Serious adverse events
- Venous thromboembolism (deep venous thrombosis, pulmonary embolism, retinal vein thrombosis)
Key clinical trials
- Comparison of Tibolone and Raloxifene on Bone Mineral Density in Osteopenic Postmenopausal Women (P06090) (PHASE4)
- Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women (PHASE3)
- Effect of Raloxifene Plus Cholecalciferol and Cholecalciferol Alone on the Bone Mineral Density in Postmenopausal Women With Osteopenia (PHASE4)
- DP-R213 Phase 1 Pharmacokinetics Study (PHASE1)
- DP-R213 Pharmacokinetics Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- raloxifen CI brief — competitive landscape report
- raloxifen updates RSS · CI watch RSS
- Organon and Co portfolio CI